Zalevsky Jonathan 4
4 · NEKTAR THERAPEUTICS · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Nektar Therapeutics (NKTR) Chief R&D Officer Jonathan Zalevsky Sells Shares
What Happened
- Jonathan Zalevsky, Chief Research & Development Officer of Nektar Therapeutics (NKTR), sold 5,538 shares in an open‑market transaction on June 15, 2026. The weighted average sale price was $60.71 per share, for total proceeds of approximately $336,212. This was a sale (not a purchase), executed pursuant to a pre‑arranged trading plan.
Key Details
- Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (no late filing indicated).
- Shares sold: 5,538; weighted average price: $60.71; total value: ~$336,212.
- Price range: individual trades executed between $60.06 and $61.36 (weighted average reported).
- Footnote: Sale was made under a Rule 10b5‑1 trading plan adopted March 13, 2026; reporting person will provide detailed trade-by-trade prices/quantities on request.
- Shares owned after transaction: not specified in the provided filing.
Context
- A 10b5‑1 plan allows insiders to sell shares according to a pre‑set schedule and is commonly used to avoid trading based on nonpublic information; such sales are often routine and do not by themselves indicate management sentiment about the company.
Insider Transaction Report
Form 4
Zalevsky Jonathan
Chief R&D Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-06-15$60.71/sh−5,538$336,212→ 15,437 total
Footnotes (2)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
- [F2]This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Signature
Elizabeth Zhang, Attorney-in-Fact|2026-06-17